An experimental Alzheimer’s treatment known as dimebon is set to begin clinical trials.
Dimebon or dimebolin hydrochloride is an older Russian drug that was commonly used as an antihistamine. Dimebon has shown to have successes in preventing brain cell deaths associated with brain diseases such as Alzheimer’s.
Both pre-clinical trials and Russian research has shown dimebon as a promising new Alzheimer’s treatment. When used to treat Alzheimer’s patients, dimebon resulted in improved thinking, memory and behavioral functions in early to mid-stage Alzheimer’s patients.
Entering into clinical trials as an Alzheimer’s disease treatment, dimebon is hoped to provide a new therapy for Alzheimer’s disease within the next 10 years.
Recent Comments